MAX-40279

CAT: 0804-HY-145723-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-145723-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MAX-40279 is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201) . MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT) . MAX-40279 can be used for the research of acute myelogenous leukemia (AML) [1][2][3].
CAS Number
[2070931-57-4]
UNSPSC
12352005
Target
FGFR; FLT3
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/max-40279.html
Purity
97.04
Solubility
DMSO : ≥ 25 mg/mL
Smiles
FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
Molecular Formula
C22H23FN6OS
Molecular Weight
438.52
References & Citations
[1]Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.|[2]Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.|[3]Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15 (2) :745-765.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Popular Products